Description

Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).

Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).

Transfection Reagent for RD Cells (Muscle Rhabdomyosarcoma Cells, CCL-136)

• Two component formulation enhances lipid mediated transfection efficiency
• Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
• Kit includes Transfection Enhancer reagent and recommended transfection protocol
• High transfection efficacy in the presence of serum
• Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
• Reproducible transfection results
• Works well for standard reverse transfection and high-throughput applications
• Download in vitro RD transfection protocol: [PDF]
• Download RD CRISPR/Cas9 transfection protocol: [PDF]
• Download PowerPoint presentation for RD cells transfection kit: [PPT]
• Developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 81% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems RD Transfection Protocol: [PDF]

Download MSDS: [PDF]

RD Cell Line:

Rhabdomyosarcoma (RMS) is a rare form of pediatric cancer that develops from skeletal muscles, with embryonal rhabdomyosarcoma (ERMS) affecting children five and under and being the most common type. Approximately 350 new cases of rhabdomyosarcoma are detected every year in the United States, accounting for roughly 3% of all pediatric malignancies, as indicated by the American Cancer Society (ACS). The RD cell line is useful in preclinical research that aims to discover novel cancer drugs. The RD cell line was obtained from the muscle tissue of a 7-year-old Caucasian female with rhabdomyosarcoma and produces both myosin ATPase and myoglobin. In addition to being unstable, the RD cell line is susceptible to different viruses, such as vaccinia virus, herpes simplex virus, or human poliovirus 1. RD cells exhibit both spindle cell and large multinucleated cell morphology. Altogen Biosystems manufactures pre-optimized transfection kits with high transfection efficiencies, including the RD transfection kit for rhabdomyosarcoma cells.

Data:

Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into RD cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).

Figure 2. Protein expression of Lamin A/C in RD cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into RD cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Altogen Biosystems:
Altogen Biosystems is a life sciences company that manufactures over 100 cell type specific and pre-optimized transfection kits, electroporation buffers, and targeted in vivo delivery kits and reagents. Advanced formulation of reagents and optimized transfection protocols provide highly efficient intracellular delivery of biomolecules (proteins, DNA, mRNA, shRNA and siRNA, and small molecule compounds). Read more about transfection technology at Altogen’s Transfection Resource.

Altogen Labs Research Services:

Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

• 0.5 ml (Catalog #6901)
• 1.5 ml (Catalog #6902)
• 1.5 ml CRISPR (Catalog #2191)
• 8.0 ml (Catalog #7084)

AltogenBiosystems是一家开发和制造用于生命科学研究，药物发现和开发的转染试剂盒的生物技术公司。转染试剂盒针对特定癌细胞系和原代细胞培养进行了优化，可将生物分子有效递送到靶组织中。通过先进的试剂配方和优化的转染方案实现体外（癌细胞系）和体内（动物组织靶向试剂、癌细胞系）递送货物分子，包括质粒DNA，各种类型的RNA（mRNA，siRNA，shRNA，microRNA），蛋白质和小分子研究。 

Altogen生命科学公司致力于研发，生产和销售特定细胞系的转染试剂，用于细胞间生物分子的传递，并通过对转染试剂类型的设计将siRNA和质粒DNA有效地转入不同的细胞系和原代细胞内。Altogen公司开发的聚合物，脂质体，纳米粒子为基础的转染技术分别针对分子生物学，组合化学，和细胞生物学而分别应用。Altogen定制服务提供符合GLP要求定制研究服务，包括代稳定的细胞系，细胞银行和冷冻保存，焦磷酸测序，克隆，RNA干扰（RNAi）和基因沉默服务，发展分析，siRNA文库筛选，并转染服务。稳定的肿瘤细胞株和原代细胞的产生，可以是非常昂贵和费时。该公司的细胞培养科学家的细胞株的选择，无论是利息或shRNA表达载体的稳定表达的基因改造。标准的RNAi技术服务，包括设计与合成的siRNA的利益，验证siRNA的沉默效率，siRNA转染条件的优化，使高效的基因沉默细胞系或原代培养细胞的靶基因。转染培养细胞的瞬时或稳定的引入外源性分子和遗传物质（即RNA或DNA），通常是在生物实验室用来研究基因功能，基因表达的调节，生化映射，突变分析，和蛋白质的生产。科学家利用各种载体分子，这种分子，使质粒DNA（PDNA），信使RNA（mRNA），短干扰RNA（siRNA），小分子RNA（miRNA）的，并进入肿瘤细胞株和原代细胞的蛋白质的基因交付。不幸的是，无单提货的方法或转染试剂，可以适用于所有类型的细胞，细胞的细胞毒性和转染效率显着不同，取决于试剂，协议，并正在利用细胞类型。Altogen生物系统公司提供超过60种类型的细胞的预优化转染试剂盒。纳米粒子，脂质和聚合物基ALTOGEN®在体内转染试剂，使交付功能的RNA和DNA分子在体内。PEG脂质体在体内输送系统减少由于PEG修饰的先天免疫反应，并提供高效的siRNA转染的DNA，并在体内的蛋白质。由科学“杂志（2010年12月17日）：PEG脂质体在体内转染试剂盒siRNA的特色Altogen生物系统功能的特定细胞系转染试剂盒

120+细胞转染试剂和活体组织靶向试剂盒制造商AltogenBiosystems是一家生物技术公司，开发和制造用于生命科学研究、药物发现和开发的转染试剂盒。Altogen®体内转染试剂可有效地将生物分子导入靶组织。细胞转染试剂盒针对特定的癌细胞系和原代细胞进行了优化。通过先进的试剂配方和优化的转染方案实现货物分子（DNA、RNA、蛋白质）的高效传递。AltogenBiosystems利用高分子化学、分子和细胞生物学的专业知识，开发了新的体内外给药技术。转染是将外源分子导入培养细胞中，常用于研究基因功能、基因表达调控、生化定位和蛋白质生产。不幸的是，由于细胞毒性和转染效率的差异很大，并且取决于所使用的试剂、方案和细胞类型，因此没有一种单一的传递方法或转染试剂可应用于所有类型的细胞。AltogenBiosystems为120多个癌细胞系和原代细胞类型提供优化的转染试剂盒和电穿孔产品。体内转染试剂可实现组织靶向给药。Altogen的转染试剂盒包括用于体外（癌细胞系）和体内（用于动物研究的组织靶向试剂）转染的转染增强剂试剂和转染复合物冷凝器。Altogen实验室提供符合GLP的实验室合同研究服务。我们的生物CRO服务包括异种移植物的疗效、IND应用的pharm/tox研究和安全性测试、分析开发（ELISA、IC-50、qPCR）、90多个异种移植物动物模型、RNAi和基因沉默服务。Altogen的细胞培养科学家通过在28天内培育出稳定的细胞系，将选择的细胞系转化为稳定表达感兴趣的基因。